Dr. Carol is a neurosurgeon with over 30 years of experience in medical device services in both publicly traded and privately held companies. He comes to the Foundation from SonaCare Medical (SCM), where he was CEO for six years. During that time, SCM achieved FDA clearance in the US for its lead focused ultrasound technology for use in the treatment of prostate cancer, reimbursement codes for the technology, and regulatory authorization in China and in many other countries around the world. Dr. Carol also led efforts at SCM to bring focused ultrasound to play in the treatment of rectal cancer, kidney cancer, and peripheral vascular disease. Prior to SCM, Dr. Carol spent 20 years in the field of radiation oncology, where he was instrumental in several of the seminal developments in the field, including intensity modulated radiation therapy, image-guided radiation therapy, and inverse treatment planning. He was trained as a neurosurgeon at the University of Maryland, later combining his training and technology bent in the early days of stereotactic radiation therapy and stereotaxis to develop innovations in frameless and image-guided stereotactic surgery.
Dr. Carol received his BA with high honors as an Independent Scholar at Amherst College and his MD with Distinction in Research from the University of Rochester.
“I have a profound belief that there is the potential for therapeutic ultrasound to play a role in almost every medical therapeutic intervention,” said Dr. Carol. “I look forward to assisting the Foundation’s activities aimed at easing the path to commercialization in the focused ultrasound space.”
Related Articles:
Profile: SonaCare CEO Mark Carol